{"id":"W4410804033","doi":"10.1200/jco.2025.43.16_suppl.6020","title":"Dose expansion data from iintune-1, a phase 1/2 study of the STING agonist dazostinag plus pembrolizumab as first-line (1L), in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (RM-SCCHN).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Pembrolizumab; Agonist; Oncology; Internal medicine; Basal cell; Cancer; Immunotherapy; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001715652,0.001110643,0.001332344,0.0003728742,0.0004998209,0.0008470971,0.0008622323,0.001055315,0.003630986],"category_scores_gemma":[0.0009185913,0.000424081,0.00133022,0.0004363173,0.0005351614,0.0007471004,0.0003623957,0.002803108,0.000928732],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000883035,"about_ca_system_score_gemma":0.001175094,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001102862,"about_ca_topic_score_gemma":0.004294375,"domain_scores_codex":[0.999512,0.0002440205,0.00002775713,0.00006090328,0.00006747438,0.00008797683],"domain_scores_gemma":[0.999131,0.0001572245,0.0002136923,0.0001026236,0.00007168844,0.00032382],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4012256,0.1159097,0.0352866,0.002263025,0.002745213,0.0009279832,0.001354145,0.008511052,0.1830432,0.0004576191,0.01672556,0.2315504],"study_design_scores_gemma":[0.2006864,0.6747469,0.07886615,0.0001818171,0.001396732,0.001713539,0.0002424341,0.001742944,0.02065309,0.000361068,0.01933039,0.00007853466],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.985669,0.002744937,0.0006180273,0.0004185778,0.00007224992,0.003301086,0.003262036,0.00009193333,0.003822094],"genre_scores_gemma":[0.9753554,0.002686941,0.002339925,0.001048121,0.0001088372,0.003068638,0.01080091,0.0000613099,0.004529776],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003630986,"threshold_uncertainty_score":0.01214689,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0827834370328013,"score_gpt":0.4087412472758039,"score_spread":0.3259578102430025,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}